3gl6 › Citations

Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger.

Wang GG, Song J, Wang Z, Dormann HL, Casadio F, Li H, Luo JL, Patel DJ, Allis CD
Nature 459 847-51 (2009)
Related entries: 2kgg, 2kgi

Cited: 290 times
EuropePMC logo PMID: 19430464

Abstract

Histone H3 lysine 4 methylation (H3K4me) has been proposed as a critical component in regulating gene expression, epigenetic states, and cellular identities1. The biological meaning of H3K4me is interpreted by conserved modules including plant homeodomain (PHD) fingers that recognize varied H3K4me states. The dysregulation of PHD fingers has been implicated in several human diseases, including cancers and immune or neurological disorders. Here we report that fusing an H3K4-trimethylation (H3K4me3)-binding PHD finger, such as the carboxy-terminal PHD finger of PHF23 or JARID1A (also known as KDM5A or RBBP2), to a common fusion partner nucleoporin-98 (NUP98) as identified in human leukaemias, generated potent oncoproteins that arrested haematopoietic differentiation and induced acute myeloid leukaemia in murine models. In these processes, a PHD finger that specifically recognizes H3K4me3/2 marks was essential for leukaemogenesis. Mutations in PHD fingers that abrogated H3K4me3 binding also abolished leukaemic transformation. NUP98-PHD fusion prevented the differentiation-associated removal of H3K4me3 at many loci encoding lineage-specific transcription factors (Hox(s), Gata3, Meis1, Eya1 and Pbx1), and enforced their active gene transcription in murine haematopoietic stem/progenitor cells. Mechanistically, NUP98-PHD fusions act as 'chromatin boundary factors', dominating over polycomb-mediated gene silencing to 'lock' developmentally critical loci into an active chromatin state (H3K4me3 with induced histone acetylation), a state that defined leukaemia stem cells. Collectively, our studies represent, to our knowledge, the first report that deregulation of the PHD finger, an 'effector' of specific histone modification, perturbs the epigenetic dynamics on developmentally critical loci, catastrophizes cellular fate decision-making, and even causes oncogenesis during mammalian development.

Reviews - 3gl6 mentioned but not cited (4)

  1. Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Chi P, Allis CD, Wang GG. Nat. Rev. Cancer 10 457-469 (2010)
  2. PHD fingers: epigenetic effectors and potential drug targets. Musselman CA, Kutateladze TG. Mol. Interv. 9 314-323 (2009)
  3. Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Andreoli F, Barbosa AJ, Parenti MD, Del Rio A. Curr. Pharm. Des. 19 578-613 (2013)
  4. Chemical tools targeting readers of lysine methylation. Ortiz G, Kutateladze TG, Fujimori DG. Curr Opin Chem Biol 74 102286 (2023)

Articles - 3gl6 mentioned but not cited (8)

  1. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Wang GG, Song J, Wang Z, Dormann HL, Casadio F, Li H, Luo JL, Patel DJ, Allis CD. Nature 459 847-851 (2009)
  2. A bioinformatic and mechanistic study elicits the antifibrotic effect of ursolic acid through the attenuation of oxidative stress with the involvement of ERK, PI3K/Akt, and p38 MAPK signaling pathways in human hepatic stellate cells and rat liver. He W, Shi F, Zhou ZW, Li B, Zhang K, Zhang X, Ouyang C, Zhou SF, Zhu X. Drug Des Devel Ther 9 3989-4104 (2015)
  3. Identification of family-determining residues in PHD fingers. Slama P, Geman D. Nucleic Acids Res. 39 1666-1679 (2011)
  4. Molecular Insights into Inhibition of the Methylated Histone-Plant Homeodomain Complexes by Calixarenes. Ali M, Daze KD, Strongin DE, Rothbart SB, Rincon-Arano H, Allen HF, Li J, Strahl BD, Hof F, Kutateladze TG. J. Biol. Chem. 290 22919-22930 (2015)
  5. The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. Chakraborty S, Rendón-Ramírez A, Ásgeirsson B, Dutta M, Ghosh AS, Oda M, Venkatramani R, Rao BJ, Dandekar AM, Goñi FM. F1000Res 2 286 (2013)
  6. Covalent labeling of a chromatin reader domain using proximity-reactive cyclic peptides. Zhang MY, Yang H, Ortiz G, Trnka MJ, Petronikolou N, Burlingame AL, DeGrado WF, Fujimori DG. Chem Sci 13 6599-6609 (2022)
  7. Mechanistic insights into chromatin targeting by leukemic NUP98-PHF23 fusion. Zhang Y, Guo Y, Gough SM, Zhang J, Vann KR, Li K, Cai L, Shi X, Aplan PD, Wang GG, Kutateladze TG. Nat Commun 11 3339 (2020)
  8. Reading and erasing of the phosphonium analogue of trimethyllysine by epigenetic proteins. Belle R, Kamps JJAG, Poater J, Kumar K, Pieters BJGE, Salah E, Claridge TDW, Paton RS, Matthias Bickelhaupt F, Kawamura A, Schofield CJ, Mecinović J. Commun Chem 5 s42004-022-00640-4 (2022)


Reviews citing this publication (104)

  1. Cancer epigenetics: from mechanism to therapy. Dawson MA, Kouzarides T. Cell 150 12-27 (2012)
  2. Histone methylation: a dynamic mark in health, disease and inheritance. Greer EL, Shi Y. Nat. Rev. Genet. 13 343-357 (2012)
  3. Epigenetic protein families: a new frontier for drug discovery. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Nat Rev Drug Discov 11 384-400 (2012)
  4. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Sauvageau M, Sauvageau G. Cell Stem Cell 7 299-313 (2010)
  5. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Feinberg AP, Koldobskiy MA, Göndör A. Nat. Rev. Genet. 17 284-299 (2016)
  6. Histone demethylases in development and disease. Pedersen MT, Helin K. Trends Cell Biol. 20 662-671 (2010)
  7. The PHD finger: a versatile epigenome reader. Sanchez R, Zhou MM. Trends Biochem. Sci. 36 364-372 (2011)
  8. Histone lysine methylation and demethylation pathways in cancer. Varier RA, Timmers HT. Biochim. Biophys. Acta 1815 75-89 (2011)
  9. Readout of epigenetic modifications. Patel DJ, Wang Z. Annu. Rev. Biochem. 82 81-118 (2013)
  10. Histone onco-modifications. Füllgrabe J, Kavanagh E, Joseph B. Oncogene 30 3391-3403 (2011)
  11. NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. Gough SM, Slape CI, Aplan PD. Blood 118 6247-6257 (2011)
  12. Lysine methylation: beyond histones. Zhang X, Wen H, Shi X. Acta Biochim. Biophys. Sin. (Shanghai) 44 14-27 (2012)
  13. Histone modifications for human epigenome analysis. Kimura H. J. Hum. Genet. 58 439-445 (2013)
  14. Handpicking epigenetic marks with PHD fingers. Musselman CA, Kutateladze TG. Nucleic Acids Res. 39 9061-9071 (2011)
  15. Epigenetic aberrations during oncogenesis. Hatziapostolou M, Iliopoulos D. Cell. Mol. Life Sci. 68 1681-1702 (2011)
  16. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Wilting RH, Dannenberg JH. Drug Resist. Updat. 15 21-38 (2012)
  17. bHLH-PAS proteins in cancer. Bersten DC, Sullivan AE, Peet DJ, Whitelaw ML. Nat. Rev. Cancer 13 827-841 (2013)
  18. Breaking the histone code with quantitative mass spectrometry. Britton LM, Gonzales-Cope M, Zee BM, Garcia BA. Expert Rev Proteomics 8 631-643 (2011)
  19. Therapeutic strategies to inhibit MYC. McKeown MR, Bradner JE. Cold Spring Harb Perspect Med 4 (2014)
  20. Keeping it in the family: diverse histone recognition by conserved structural folds. Yap KL, Zhou MM. Crit. Rev. Biochem. Mol. Biol. 45 488-505 (2010)
  21. The role of nuclear pores in gene regulation, development and disease. Capelson M, Hetzer MW. EMBO Rep. 10 697-705 (2009)
  22. Gene regulation by nucleoporins and links to cancer. Köhler A, Hurt E. Mol. Cell 38 6-15 (2010)
  23. Histone modifications and DNA double-strand break repair after exposure to ionizing radiations. Hunt CR, Ramnarain D, Horikoshi N, Iyengar P, Pandita RK, Shay JW, Pandita TK. Radiat. Res. 179 383-392 (2013)
  24. Inhibitors of histone demethylases. Lohse B, Kristensen JL, Kristensen LH, Agger K, Helin K, Gajhede M, Clausen RP. Bioorg. Med. Chem. 19 3625-3636 (2011)
  25. Grasping trimethylation of histone H3 at lysine 4. Vermeulen M, Timmers HT. Epigenomics 2 395-406 (2010)
  26. Tudor: a versatile family of histone methylation 'readers'. Lu R, Wang GG. Trends Biochem. Sci. 38 546-555 (2013)
  27. Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Deshpande AJ, Bradner J, Armstrong SA. Trends Immunol. 33 563-570 (2012)
  28. Functional coupling between writers, erasers and readers of histone and DNA methylation. Torres IO, Fujimori DG. Curr. Opin. Struct. Biol. 35 68-75 (2015)
  29. Nuclear trafficking in health and disease. Mor A, White MA, Fontoura BM. Curr. Opin. Cell Biol. 28 28-35 (2014)
  30. Nucleoporin Nup98: a gatekeeper in the eukaryotic kingdoms. Iwamoto M, Asakawa H, Hiraoka Y, Haraguchi T. Genes Cells 15 661-669 (2010)
  31. Chromatin modifiers and the promise of epigenetic therapy in acute leukemia. Greenblatt SM, Nimer SD. Leukemia 28 1396-1406 (2014)
  32. Many keys to push: diversifying the 'readership' of plant homeodomain fingers. Li Y, Li H. Acta Biochim. Biophys. Sin. (Shanghai) 44 28-39 (2012)
  33. Structural and functional coordination of DNA and histone methylation. Cheng X. Cold Spring Harb Perspect Biol 6 (2014)
  34. Chromatin and oxygen sensing in the context of JmjC histone demethylases. Shmakova A, Batie M, Druker J, Rocha S. Biochem. J. 462 385-395 (2014)
  35. The role of histone modifications and variants in regulating gene expression in breast cancer. Dalvai M, Bystricky K. J Mammary Gland Biol Neoplasia 15 19-33 (2010)
  36. The biology of pediatric acute megakaryoblastic leukemia. Gruber TA, Downing JR. Blood 126 943-949 (2015)
  37. Key roles of histone methyltransferase and demethylase in leukemogenesis. Yoshimi A, Kurokawa M. J. Cell. Biochem. 112 415-424 (2011)
  38. The role of chromatin modifiers in normal and malignant hematopoiesis. Butler JS, Dent SY. Blood 121 3076-3084 (2013)
  39. A Structural Perspective on Readout of Epigenetic Histone and DNA Methylation Marks. Patel DJ. Cold Spring Harb Perspect Biol 8 a018754 (2016)
  40. Diverse functions of PHD fingers of the MLL/KMT2 subfamily. Ali M, Hom RA, Blakeslee W, Ikenouye L, Kutateladze TG. Biochim. Biophys. Acta 1843 366-371 (2014)
  41. Mind the methyl: methyllysine binding proteins in epigenetic regulation. Wagner T, Robaa D, Sippl W, Jung M. ChemMedChem 9 466-483 (2014)
  42. Epigenetics in the hematologic malignancies. Fong CY, Morison J, Dawson MA. Haematologica 99 1772-1783 (2014)
  43. Histone demethylases in chromatin cross-talks. Verrier L, Vandromme M, Trouche D. Biol. Cell 103 381-401 (2011)
  44. A chemical probe toolbox for dissecting the cancer epigenome. Shortt J, Ott CJ, Johnstone RW, Bradner JE. Nat. Rev. Cancer 17 160-183 (2017)
  45. Transcriptional and epigenetic networks in haematological malignancy. Cheung N, So CW. FEBS Lett. 585 2100-2111 (2011)
  46. Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development. Barry ER, Corry GN, Rasmussen TP. Expert Opin. Ther. Targets 14 405-418 (2010)
  47. Functional proteomics of the epigenetic regulators ASXL1, ASXL2 and ASXL3: a convergence of proteomics and epigenetics for translational medicine. Katoh M. Expert Rev Proteomics 12 317-328 (2015)
  48. Jumonji histone demethylases as emerging therapeutic targets. Park SY, Park JW, Chun YS. Pharmacol. Res. 105 146-151 (2016)
  49. Nucleoporins and nucleocytoplasmic transport in hematologic malignancies. Takeda A, Yaseen NR. Semin. Cancer Biol. 27 3-10 (2014)
  50. Small-molecular modulators of cancer-associated epigenetic mechanisms. Itoh Y, Suzuki T, Miyata N. Mol Biosyst 9 873-896 (2013)
  51. The language of chromatin modification in human cancers. Zhao S, Allis CD, Wang GG. Nat Rev Cancer 21 413-430 (2021)
  52. Roles of histone methyl-modifying enzymes in development and progression of cancer. Suzuki T, Terashima M, Tange S, Ishimura A. Cancer Sci. 104 795-800 (2013)
  53. Targeting chromatin readers. James LI, Frye SV. Clin. Pharmacol. Ther. 93 312-314 (2013)
  54. Hox gene dysregulation in acute myeloid leukemia. De Braekeleer E, Douet-Guilbert N, Basinko A, Le Bris MJ, Morel F, De Braekeleer M. Future Oncol 10 475-495 (2014)
  55. Drugging the human methylome: an emerging modality for reversible control of aberrant gene transcription. Wigle TJ, Copeland RA. Curr Opin Chem Biol 17 369-378 (2013)
  56. Recent advances in the ARID family: focusing on roles in human cancer. Lin C, Song W, Bi X, Zhao J, Huang Z, Li Z, Zhou J, Cai J, Zhao H. Onco Targets Ther 7 315-324 (2014)
  57. H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer. Nichol JN, Dupéré-Richer D, Ezponda T, Licht JD, Miller WH. Adv. Cancer Res. 131 59-95 (2016)
  58. Progress in epigenetic histone modification analysis by mass spectrometry for clinical investigations. Önder Ö, Sidoli S, Carroll M, Garcia BA. Expert Rev Proteomics 12 499-517 (2015)
  59. Epigenetic Mechanisms in Developmental Alcohol-Induced Neurobehavioral Deficits. Basavarajappa BS, Subbanna S. Brain Sci 6 (2016)
  60. JARID1 Histone Demethylases: Emerging Targets in Cancer. Harmeyer KM, Facompre ND, Herlyn M, Basu D. Trends Cancer 3 713-725 (2017)
  61. Environmental sensing by chromatin: an epigenetic contribution to evolutionary change. Turner BM. FEBS Lett. 585 2032-2040 (2011)
  62. The Chemical Biology of Reversible Lysine Post-translational Modifications. Wang ZA, Cole PA. Cell Chem Biol 27 953-969 (2020)
  63. Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases. Bellows ML, Floudas CA. Curr Drug Targets 11 264-278 (2010)
  64. Histone-modifying enzymes: their role in the pathogenesis of acute leukemia and their therapeutic potential. Vu LP, Luciani L, Nimer SD. Int. J. Hematol. 97 198-209 (2013)
  65. Mechanisms of epigenetic regulation of leukemia onset and progression. Ntziachristos P, Mullenders J, Trimarchi T, Aifantis I. Adv. Immunol. 117 1-38 (2013)
  66. Selective targeting of epigenetic reader domains. Greschik H, Schüle R, Günther T. Expert Opin Drug Discov 12 449-463 (2017)
  67. DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics. Bhattacharjee D, Shenoy S, Bairy KL. Scientifica (Cairo) 2016 6072357 (2016)
  68. Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia. Lu R, Wang GG. Front Oncol 7 241 (2017)
  69. Targeting epigenetic protein-protein interactions with small-molecule inhibitors. Linhares BM, Grembecka J, Cierpicki T. Future Med Chem 12 1305-1326 (2020)
  70. Concise Review: Geminin-A Tale of Two Tails: DNA Replication and Transcriptional/Epigenetic Regulation in Stem Cells. Patmanidi AL, Champeris Tsaniras S, Karamitros D, Kyrousi C, Lygerou Z, Taraviras S. Stem Cells 35 299-310 (2017)
  71. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. Zhao A, Zhou H, Yang J, Li M, Niu T. Signal Transduct Target Ther 8 71 (2023)
  72. Histone Methylation Regulation in Neurodegenerative Disorders. Basavarajappa BS, Subbanna S. Int J Mol Sci 22 4654 (2021)
  73. SGF29 and Sry pathway in hepatocarcinogenesis. Kurabe N, Murakami S, Tashiro F. World J Biol Chem 6 139-147 (2015)
  74. Acute Megakaryocytic Leukemia. McNulty M, Crispino JD. Cold Spring Harb Perspect Med 10 a034884 (2020)
  75. Allosteric regulation of epigenetic modifying enzymes. Zucconi BE, Cole PA. Curr Opin Chem Biol 39 109-115 (2017)
  76. Making Connections: Integrative Signaling Mechanisms Coordinate DNA Break Repair in Chromatin. Sanchez A, Lee D, Kim DI, Miller KM. Front Genet 12 747734 (2021)
  77. Regulatory variation: an emerging vantage point for cancer biology. Li L, Lorzadeh A, Hirst M. Wiley Interdiscip Rev Syst Biol Med 6 37-59 (2014)
  78. Synthetic chromatin approaches to probe the writing and erasing of histone modifications. Fierz B. ChemMedChem 9 495-504 (2014)
  79. Targeting epigenetics using synthetic lethality in precision medicine. Chen ES. Cell. Mol. Life Sci. 75 3381-3392 (2018)
  80. Understanding the interplay between CpG island-associated gene promoters and H3K4 methylation. Hughes AL, Kelley JR, Klose RJ. Biochim Biophys Acta Gene Regul Mech 1863 194567 (2020)
  81. Diverse Functions of KDM5 in Cancer: Transcriptional Repressor or Activator? Ohguchi Y, Ohguchi H. Cancers (Basel) 14 3270 (2022)
  82. Histone methylation in pancreatic cancer and its clinical implications. Liu XY, Guo CH, Xi ZY, Xu XQ, Zhao QY, Li LS, Wang Y. World J Gastroenterol 27 6004-6024 (2021)
  83. Intrinsic Disorder-Based Emergence in Cellular Biology: Physiological and Pathological Liquid-Liquid Phase Transitions in Cells. Darling AL, Zaslavsky BY, Uversky VN. Polymers (Basel) 11 (2019)
  84. Investigations on small molecule inhibitors targeting the histone H3K4 tri-methyllysine binding PHD-finger of JmjC histone demethylases. Bhushan B, Erdmann A, Zhang Y, Belle R, Johannson C, Oppermann U, Hopkinson RJ, Schofield CJ, Kawamura A. Bioorg. Med. Chem. 26 2984-2991 (2018)
  85. Pediatric Acute Megakaryoblastic Leukemia: Multitasking Fusion Proteins and Oncogenic Cooperations. Lopez CK, Malinge S, Gaudry M, Bernard OA, Mercher T. Trends Cancer 3 631-642 (2017)
  86. Recent developments in catalysis and inhibition of the Jumonji histone demethylases. Sarah L, Fujimori DG. Curr Opin Struct Biol 83 102707 (2023)
  87. Structural aspects of small-molecule inhibition of methyllysine reader proteins. Milosevich N, Warmerdam Z, Hof F. Future Med Chem 8 1681-1702 (2016)
  88. A cryptic translocation leading to NUP98-PHF23 fusion in AML. Ning Y. Best Pract Res Clin Haematol 29 320-323 (2016)
  89. Advances in molecular characterization of pediatric acute megakaryoblastic leukemia not associated with Down syndrome; impact on therapy development. Li J, Kalev-Zylinska ML. Front Cell Dev Biol 11 1170622 (2023)
  90. Catching Nucleosome by Its Decorated Tails Determines Its Functional States. Sehrawat P, Shobhawat R, Kumar A. Front Genet 13 903923 (2022)
  91. Domain architecture and protein-protein interactions regulate KDM5A recruitment to the chromatin. Kataria A, Tyagi S. Epigenetics 18 2268813 (2023)
  92. Epigenetics in myelodysplastic syndromes. Heuser M, Yun H, Thol F. Semin. Cancer Biol. 51 170-179 (2018)
  93. Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies. Markouli M, Strepkos D, Piperi C. Int J Mol Sci 23 13657 (2022)
  94. Joining the PARty: PARP Regulation of KDM5A during DNA Repair (and Transcription?). Sanchez A, Buck-Koehntop BA, Miller KM. Bioessays 44 e2200015 (2022)
  95. Multilevel view on chromatin architecture alterations in cancer. Gridina M, Fishman V. Front Genet 13 1059617 (2022)
  96. Nuclear envelope, chromatin organizers, histones, and DNA: The many achilles heels exploited across cancers. Balaji AK, Saha S, Deshpande S, Poola D, Sengupta K. Front Cell Dev Biol 10 1068347 (2022)
  97. Onco-condensates: formation, multi-component organization, and biological functions. Xu C, Kim A, Corbin JM, Wang GG. Trends Cancer 9 738-751 (2023)
  98. Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention. Mercher T, Schwaller J. Front Pediatr 7 401 (2019)
  99. Phase separation in immune regulation and immune-related diseases. Huang N, Dong H, Shao B. J Mol Med (Berl) 100 1427-1440 (2022)
  100. Regulation, functions and transmission of bivalent chromatin during mammalian development. Macrae TA, Fothergill-Robinson J, Ramalho-Santos M. Nat Rev Mol Cell Biol 24 6-26 (2023)
  101. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. Chang S, Yim S, Park H. Exp. Mol. Med. 51 66 (2019)
  102. The emerging role of KDM5A in human cancer. Yang GJ, Zhu MH, Lu XJ, Liu YJ, Lu JF, Leung CH, Ma DL, Chen J. J Hematol Oncol 14 30 (2021)
  103. The emerging roles of histone demethylases in cancers. Tong D, Tang Y, Zhong P. Cancer Metastasis Rev (2024)
  104. The genomics of acute myeloid leukemia in children. Conneely SE, Rau RE. Cancer Metastasis Rev 39 189-209 (2020)

Articles citing this publication (174)

  1. Quantitative interaction proteomics and genome-wide profiling of epigenetic histone marks and their readers. Vermeulen M, Eberl HC, Matarese F, Marks H, Denissov S, Butter F, Lee KK, Olsen JV, Hyman AA, Stunnenberg HG, Mann M. Cell 142 967-980 (2010)
  2. Analysis of the human endogenous coregulator complexome. Malovannaya A, Lanz RB, Jung SY, Bulynko Y, Le NT, Chan DW, Ding C, Shi Y, Yucer N, Krenciute G, Kim BJ, Li C, Chen R, Li W, Wang Y, O'Malley BW, Qin J. Cell 145 787-799 (2011)
  3. TRIM24 links a non-canonical histone signature to breast cancer. Tsai WW, Wang Z, Yiu TT, Akdemir KC, Xia W, Winter S, Tsai CY, Shi X, Schwarzer D, Plunkett W, Aronow B, Gozani O, Fischle W, Hung MC, Patel DJ, Barton MC. Nature 468 927-932 (2010)
  4. A poised chromatin platform for TGF-β access to master regulators. Xi Q, Wang Z, Zaromytidou AI, Zhang XH, Chow-Tsang LF, Liu JX, Kim H, Barlas A, Manova-Todorova K, Kaartinen V, Studer L, Mark W, Patel DJ, Massagué J. Cell 147 1511-1524 (2011)
  5. Structural basis for selective binding of m6A RNA by the YTHDC1 YTH domain. Xu C, Wang X, Liu K, Roundtree IA, Tempel W, Li Y, Lu Z, He C, Min J. Nat. Chem. Biol. 10 927-929 (2014)
  6. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Milne TA, Kim J, Wang GG, Stadler SC, Basrur V, Whitcomb SJ, Wang Z, Ruthenburg AJ, Elenitoba-Johnson KS, Roeder RG, Allis CD. Mol. Cell 38 853-863 (2010)
  7. SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. Yang F, Sun L, Li Q, Han X, Lei L, Zhang H, Shang Y. EMBO J. 31 110-123 (2012)
  8. Jarid1b targets genes regulating development and is involved in neural differentiation. Schmitz SU, Albert M, Malatesta M, Morey L, Johansen JV, Bak M, Tommerup N, Abarrategui I, Helin K. EMBO J. 30 4586-4600 (2011)
  9. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Rampal R, Alkalin A, Madzo J, Vasanthakumar A, Pronier E, Patel J, Li Y, Ahn J, Abdel-Wahab O, Shih A, Lu C, Ward PS, Tsai JJ, Hricik T, Tosello V, Tallman JE, Zhao X, Daniels D, Dai Q, Ciminio L, Aifantis I, He C, Fuks F, Tallman MS, Ferrando A, Nimer S, Paietta E, Thompson CB, Licht JD, Mason CE, Godley LA, Melnick A, Figueroa ME, Levine RL. Cell Rep 9 1841-1855 (2014)
  10. Histone demethylase KDM5A is an integral part of the core Notch-RBP-J repressor complex. Liefke R, Oswald F, Alvarado C, Ferres-Marco D, Mittler G, Rodriguez P, Dominguez M, Borggrefe T. Genes Dev. 24 590-601 (2010)
  11. An H3K36 methylation-engaging Tudor motif of polycomb-like proteins mediates PRC2 complex targeting. Cai L, Rothbart SB, Lu R, Xu B, Chen WY, Tripathy A, Rockowitz S, Zheng D, Patel DJ, Allis CD, Strahl BD, Song J, Wang GG. Mol. Cell 49 571-582 (2013)
  12. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, Chen SC, Su X, Ogden SK, Dang J, Wu G, Gupta V, Andersson AK, Pounds S, Shi L, Easton J, Barbato MI, Mulder HL, Manne J, Wang J, Rusch M, Ranade S, Ganti R, Parker M, Ma J, Radtke I, Ding L, Cazzaniga G, Biondi A, Kornblau SM, Ravandi F, Kantarjian H, Nimer SD, Döhner K, Döhner H, Ley TJ, Ballerini P, Shurtleff S, Tomizawa D, Adachi S, Hayashi Y, Tawa A, Shih LY, Liang DC, Rubnitz JE, Pui CH, Mardis ER, Wilson RK, Downing JR. Cancer Cell 22 683-697 (2012)
  13. Plant homeodomain (PHD) fingers of CHD4 are histone H3-binding modules with preference for unmodified H3K4 and methylated H3K9. Mansfield RE, Musselman CA, Kwan AH, Oliver SS, Garske AL, Davrazou F, Denu JM, Kutateladze TG, Mackay JP. J. Biol. Chem. 286 11779-11791 (2011)
  14. KDM5B regulates embryonic stem cell self-renewal and represses cryptic intragenic transcription. Xie L, Pelz C, Wang W, Bashar A, Varlamova O, Shadle S, Impey S. EMBO J. 30 1473-1484 (2011)
  15. A map of general and specialized chromatin readers in mouse tissues generated by label-free interaction proteomics. Eberl HC, Spruijt CG, Kelstrup CD, Vermeulen M, Mann M. Mol. Cell 49 368-378 (2013)
  16. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Lin W, Cao J, Liu J, Beshiri ML, Fujiwara Y, Francis J, Cherniack AD, Geisen C, Blair LP, Zou MR, Shen X, Kawamori D, Liu Z, Grisanzio C, Watanabe H, Minamishima YA, Zhang Q, Kulkarni RN, Signoretti S, Rodig SJ, Bronson RT, Orkin SH, Tuck DP, Benevolenskaya EV, Meyerson M, Kaelin WG, Yan Q. Proc. Natl. Acad. Sci. U.S.A. 108 13379-13386 (2011)
  17. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Xu B, On DM, Ma A, Parton T, Konze KD, Pattenden SG, Allison DF, Cai L, Rockowitz S, Liu S, Liu Y, Li F, Vedadi M, Frye SV, Garcia BA, Zheng D, Jin J, Wang GG. Blood 125 346-357 (2015)
  18. Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation. Pospisil V, Vargova K, Kokavec J, Rybarova J, Savvulidi F, Jonasova A, Necas E, Zavadil J, Laslo P, Stopka T. EMBO J. 30 4450-4464 (2011)
  19. JARID1B is a luminal lineage-driving oncogene in breast cancer. Yamamoto S, Wu Z, Russnes HG, Takagi S, Peluffo G, Vaske C, Zhao X, Moen Vollan HK, Maruyama R, Ekram MB, Sun H, Kim JH, Carver K, Zucca M, Feng J, Almendro V, Bessarabova M, Rueda OM, Nikolsky Y, Caldas C, Liu XS, Polyak K. Cancer Cell 25 762-777 (2014)
  20. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Wang QF, Wu G, Mi S, He F, Wu J, Dong J, Luo RT, Mattison R, Kaberlein JJ, Prabhakar S, Ji H, Thirman MJ. Blood 117 6895-6905 (2011)
  21. Essential functions of the histone demethylase lid. Li L, Greer C, Eisenman RN, Secombe J. PLoS Genet. 6 e1001221 (2010)
  22. Epigenetic Regulation by Lysine Demethylase 5 (KDM5) Enzymes in Cancer. Blair LP, Cao J, Zou MR, Sayegh J, Yan Q. Cancers (Basel) 3 1383-1404 (2011)
  23. Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines. Liu F, Barsyte-Lovejoy D, Allali-Hassani A, He Y, Herold JM, Chen X, Yates CM, Frye SV, Brown PJ, Huang J, Vedadi M, Arrowsmith CH, Jin J. J. Med. Chem. 54 6139-6150 (2011)
  24. Structural insight into the zinc finger CW domain as a histone modification reader. He F, Umehara T, Saito K, Harada T, Watanabe S, Yabuki T, Kigawa T, Takahashi M, Kuwasako K, Tsuda K, Matsuda T, Aoki M, Seki E, Kobayashi N, Güntert P, Yokoyama S, Muto Y. Structure 18 1127-1139 (2010)
  25. The X-linked mental retardation gene PHF8 is a histone demethylase involved in neuronal differentiation. Qiu J, Shi G, Jia Y, Li J, Wu M, Li J, Dong S, Wong J. Cell Res. 20 908-918 (2010)
  26. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. de Rooij JD, Hollink IH, Arentsen-Peters ST, van Galen JF, Berna Beverloo H, Baruchel A, Trka J, Reinhardt D, Sonneveld E, Zimmermann M, Alonzo TA, Pieters R, Meshinchi S, van den Heuvel-Eibrink MM, Zwaan CM. Leukemia 27 2280-2288 (2013)
  27. The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers. Klein BJ, Piao L, Xi Y, Rincon-Arano H, Rothbart SB, Peng D, Wen H, Larson C, Zhang X, Zheng X, Cortazar MA, Peña PV, Mangan A, Bentley DL, Strahl BD, Groudine M, Li W, Shi X, Kutateladze TG. Cell Rep 6 325-335 (2014)
  28. Quantitative chemical proteomics approach to identify post-translational modification-mediated protein-protein interactions. Li X, Foley EA, Molloy KR, Li Y, Chait BT, Kapoor TM. J. Am. Chem. Soc. 134 1982-1985 (2012)
  29. Histone demethylase RBP2 is critical for breast cancer progression and metastasis. Cao J, Liu Z, Cheung WK, Zhao M, Chen SY, Chan SW, Booth CJ, Nguyen DX, Yan Q. Cell Rep 6 868-877 (2014)
  30. The KDM5 family of histone demethylases as targets in oncology drug discovery. Rasmussen PB, Staller P. Epigenomics 6 277-286 (2014)
  31. Double-strand break-induced transcriptional silencing is associated with loss of tri-methylation at H3K4. Seiler DM, Rouquette J, Schmid VJ, Strickfaden H, Ottmann C, Drexler GA, Mazurek B, Greubel C, Hable V, Dollinger G, Cremer T, Friedl AA. Chromosome Res. 19 883-899 (2011)
  32. Identification and characterization of small molecule inhibitors of a plant homeodomain finger. Wagner EK, Nath N, Flemming R, Feltenberger JB, Denu JM. Biochemistry 51 8293-8306 (2012)
  33. Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development. Lu R, Wang P, Parton T, Zhou Y, Chrysovergis K, Rockowitz S, Chen WY, Abdel-Wahab O, Wade PA, Zheng D, Wang GG. Cancer Cell 30 92-107 (2016)
  34. Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. Thiollier C, Lopez CK, Gerby B, Ignacimouttou C, Poglio S, Duffourd Y, Guégan J, Rivera-Munoz P, Bluteau O, Mabialah V, Diop M, Wen Q, Petit A, Bauchet AL, Reinhardt D, Bornhauser B, Gautheret D, Lecluse Y, Landman-Parker J, Radford I, Vainchenker W, Dastugue N, de Botton S, Dessen P, Bourquin JP, Crispino JD, Ballerini P, Bernard OA, Pflumio F, Mercher T. J. Exp. Med. 209 2017-2031 (2012)
  35. Coordinated repression of cell cycle genes by KDM5A and E2F4 during differentiation. Beshiri ML, Holmes KB, Richter WF, Hess S, Islam AB, Yan Q, Plante L, Litovchick L, Gévry N, Lopez-Bigas N, Kaelin WG, Benevolenskaya EV. Proc. Natl. Acad. Sci. U.S.A. 109 18499-18504 (2012)
  36. Targeting the epigenome for treatment of cancer. Geutjes EJ, Bajpe PK, Bernards R. Oncogene 31 3827-3844 (2012)
  37. RNAi screen identifies Jarid1b as a major regulator of mouse HSC activity. Cellot S, Hope KJ, Chagraoui J, Sauvageau M, Deneault É, MacRae T, Mayotte N, Wilhelm BT, Landry JR, Ting SB, Krosl J, Humphries K, Thompson A, Sauvageau G. Blood 122 1545-1555 (2013)
  38. Histone demethylase KDM5A is regulated by its reader domain through a positive-feedback mechanism. Torres IO, Kuchenbecker KM, Nnadi CI, Fletterick RJ, Kelly MJ, Fujimori DG. Nat Commun 6 6204 (2015)
  39. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor. Kristensen LH, Nielsen AL, Helgstrand C, Lees M, Cloos P, Kastrup JS, Helin K, Olsen L, Gajhede M. FEBS J. 279 1905-1914 (2012)
  40. The JmjN domain of Jhd2 is important for its protein stability, and the plant homeodomain (PHD) finger mediates its chromatin association independent of H3K4 methylation. Huang F, Chandrasekharan MB, Chen YC, Bhaskara S, Hiebert SW, Sun ZW. J. Biol. Chem. 285 24548-24561 (2010)
  41. Histone variant H2A.Z regulates centromere silencing and chromosome segregation in fission yeast. Hou H, Wang Y, Kallgren SP, Thompson J, Yates JR, Jia S. J. Biol. Chem. 285 1909-1918 (2010)
  42. Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3. James LI, Korboukh VK, Krichevsky L, Baughman BM, Herold JM, Norris JL, Jin J, Kireev DB, Janzen WP, Arrowsmith CH, Frye SV. J. Med. Chem. 56 7358-7371 (2013)
  43. A companion cell-dominant and developmentally regulated H3K4 demethylase controls flowering time in Arabidopsis via the repression of FLC expression. Yang H, Han Z, Cao Y, Fan D, Li H, Mo H, Feng Y, Liu L, Wang Z, Yue Y, Cui S, Chen S, Chai J, Ma L. PLoS Genet. 8 e1002664 (2012)
  44. Chd5 requires PHD-mediated histone 3 binding for tumor suppression. Paul S, Kuo A, Schalch T, Schalch T, Vogel H, Joshua-Tor L, McCombie WR, Gozani O, Hammell M, Mills AA. Cell Rep 3 92-102 (2013)
  45. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases. Horton JR, Engstrom A, Zoeller EL, Liu X, Shanks JR, Zhang X, Johns MA, Vertino PM, Fu H, Cheng X. J. Biol. Chem. 291 2631-2646 (2016)
  46. Chromatin modifications and the DNA damage response to ionizing radiation. Kumar R, Horikoshi N, Singh M, Gupta A, Misra HS, Albuquerque K, Hunt CR, Pandita TK. Front Oncol 2 214 (2012)
  47. NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis. Xu H, Valerio DG, Eisold ME, Sinha A, Koche RP, Hu W, Chen CW, Chu SH, Brien GL, Park CY, Hsieh JJ, Ernst P, Armstrong SA. Cancer Cell 30 863-878 (2016)
  48. Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells. Tumber A, Nuzzi A, Hookway ES, Hatch SB, Velupillai S, Johansson C, Kawamura A, Savitsky P, Yapp C, Szykowska A, Wu N, Bountra C, Strain-Damerell C, Burgess-Brown NA, Ruda GF, Fedorov O, Munro S, England KS, Nowak RP, Schofield CJ, La Thangue NB, Pawlyn C, Davies F, Morgan G, Athanasou N, Müller S, Oppermann U, Brennan PE. Cell Chem Biol 24 371-380 (2017)
  49. Re-patterning of H3K27me3, H3K4me3 and DNA methylation during fibroblast conversion into induced cardiomyocytes. Liu Z, Chen O, Zheng M, Wang L, Zhou Y, Yin C, Liu J, Qian L. Stem Cell Res 16 507-518 (2016)
  50. Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds. Horton JR, Liu X, Gale M, Wu L, Shanks JR, Zhang X, Webber PJ, Bell JSK, Kales SC, Mott BT, Rai G, Jansen DJ, Henderson MJ, Urban DJ, Hall MD, Simeonov A, Maloney DJ, Johns MA, Fu H, Jadhav A, Vertino PM, Yan Q, Cheng X. Cell Chem Biol 23 769-781 (2016)
  51. Tripartite Motif-containing 33 (TRIM33) protein functions in the poly(ADP-ribose) polymerase (PARP)-dependent DNA damage response through interaction with Amplified in Liver Cancer 1 (ALC1) protein. Kulkarni A, Oza J, Yao M, Sohail H, Ginjala V, Tomas-Loba A, Horejsi Z, Tan AR, Boulton SJ, Ganesan S. J. Biol. Chem. 288 32357-32369 (2013)
  52. Identification of a role for histone H2B ubiquitylation in noncoding RNA 3'-end formation through mutational analysis of Rtf1 in Saccharomyces cerevisiae. Tomson BN, Davis CP, Warner MH, Arndt KM. Genetics 188 273-289 (2011)
  53. Research Support, Non-U.S. Gov't Myelodysplastic syndromes: lost between two states? Acquaviva C, Gelsi-Boyer V, Birnbaum D. Leukemia 24 1-5 (2010)
  54. Phase separation drives aberrant chromatin looping and cancer development. Ahn JH, Davis ES, Daugird TA, Zhao S, Quiroga IY, Uryu H, Li J, Storey AJ, Tsai YH, Keeley DP, Mackintosh SG, Edmondson RD, Byrum SD, Cai L, Tackett AJ, Zheng D, Legant WR, Phanstiel DH, Wang GG. Nature 595 591-595 (2021)
  55. NUP98-PHF23 is a chromatin-modifying oncoprotein that causes a wide array of leukemias sensitive to inhibition of PHD histone reader function. Gough SM, Lee F, Yang F, Walker RL, Zhu YJ, Pineda M, Onozawa M, Chung YJ, Bilke S, Wagner EK, Denu JM, Ning Y, Xu B, Wang GG, Meltzer PS, Aplan PD. Cancer Discov 4 564-577 (2014)
  56. dKDM5/LID regulates H3K4me3 dynamics at the transcription-start site (TSS) of actively transcribed developmental genes. Lloret-Llinares M, Pérez-Lluch S, Rossell D, Morán T, Ponsa-Cobas J, Auer H, Corominas M, Azorín F. Nucleic Acids Res. 40 9493-9505 (2012)
  57. Coordinated methyl-lysine erasure: structural and functional linkage of a Jumonji demethylase domain and a reader domain. Upadhyay AK, Horton JR, Zhang X, Cheng X. Curr. Opin. Struct. Biol. 21 750-760 (2011)
  58. Letter NUP98-HMGB3: a novel oncogenic fusion. Petit A, Ragu C, Della-Valle V, Mozziconacci MJ, Lafage-Pochitaloff M, Soler G, Schluth C, Radford I, Ottolenghi C, Bernard OA, Penard-Lacronique V, Romana SP. Leukemia 24 654-658 (2010)
  59. Nup98-homeodomain fusions interact with endogenous Nup98 during interphase and localize to kinetochores and chromosome arms during mitosis. Xu S, Powers MA. Mol. Biol. Cell 21 1585-1596 (2010)
  60. Physical and functional interactions between the histone H3K4 demethylase KDM5A and the nucleosome remodeling and deacetylase (NuRD) complex. Nishibuchi G, Shibata Y, Hayakawa T, Hayakawa N, Ohtani Y, Sinmyozu K, Tagami H, Nakayama J. J. Biol. Chem. 289 28956-28970 (2014)
  61. Predicting distinct organization of transcription factor binding sites on the promoter regions: a new genome-based approach to expand human embryonic stem cell regulatory network. Hosseinpour B, Bakhtiarizadeh MR, Khosravi P, Ebrahimie E. Gene 531 212-219 (2013)
  62. Selective targeting of histone methylation. Islam AB, Richter WF, Lopez-Bigas N, Benevolenskaya EV. Cell Cycle 10 413-424 (2011)
  63. The role of Nup98 in transcription regulation in healthy and diseased cells. Franks TM, Hetzer MW. Trends Cell Biol. 23 112-117 (2013)
  64. HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases. Paroni G, Bolis M, Zanetti A, Ubezio P, Helin K, Staller P, Gerlach LO, Fratelli M, Neve RM, Terao M, Garattini E. Oncogene 38 2675-2689 (2019)
  65. Molecular basis for the anchoring of proto-oncoprotein Nup98 to the cytoplasmic face of the nuclear pore complex. Stuwe T, von Borzyskowski LS, Davenport AM, Hoelz A. J. Mol. Biol. 419 330-346 (2012)
  66. Drug discovery toward antagonists of methyl-lysine binding proteins. Herold JM, Ingerman LA, Gao C, Frye SV. Curr Chem Genomics 5 51-61 (2011)
  67. The Histone Demethylase KDM5 Activates Gene Expression by Recognizing Chromatin Context through Its PHD Reader Motif. Liu X, Secombe J. Cell Rep 13 2219-2231 (2015)
  68. Histone demethylases and their roles in cancer epigenetics. D'Oto A, Tian QW, Davidoff AM, Yang J. J Med Oncol Ther 1 34-40 (2016)
  69. Integrative epigenomic analysis of differential DNA methylation in urothelial carcinoma. Aine M, Sjödahl G, Eriksson P, Veerla S, Lindgren D, Ringnér M, Höglund M. Genome Med 7 23 (2015)
  70. KDM5 interacts with Foxo to modulate cellular levels of oxidative stress. Liu X, Greer C, Secombe J. PLoS Genet. 10 e1004676 (2014)
  71. Epigenetic Heterogeneity of B-Cell Lymphoma: DNA Methylation, Gene Expression and Chromatin States. Hopp L, Löffler-Wirth H, Binder H. Genes (Basel) 6 812-840 (2015)
  72. Family-wide Characterization of Histone Binding Abilities of Human CW Domain-containing Proteins. Liu Y, Tempel W, Zhang Q, Liang X, Loppnau P, Qin S, Min J. J. Biol. Chem. 291 9000-9013 (2016)
  73. Multivalent Chromatin Engagement and Inter-domain Crosstalk Regulate MORC3 ATPase. Andrews FH, Tong Q, Sullivan KD, Cornett EM, Zhang Y, Ali M, Ahn J, Pandey A, Guo AH, Strahl BD, Costello JC, Espinosa JM, Rothbart SB, Kutateladze TG. Cell Rep 16 3195-3207 (2016)
  74. RBP2 induces stem-like cancer cells by promoting EMT and is a prognostic marker for renal cell carcinoma. Zhou D, Kannappan V, Chen X, Li J, Leng X, Zhang J, Xuan S. Exp. Mol. Med. 48 e238 (2016)
  75. Chemical basis for the recognition of trimethyllysine by epigenetic reader proteins. Kamps JJ, Huang J, Poater J, Xu C, Pieters BJ, Dong A, Min J, Sherman W, Beuming T, Matthias Bickelhaupt F, Li H, Mecinović J. Nat Commun 6 8911 (2015)
  76. NUP98-MLL fusion in human acute myeloblastic leukemia. Kaltenbach S, Soler G, Barin C, Gervais C, Bernard OA, Penard-Lacronique V, Romana SP. Blood 116 2332-2335 (2010)
  77. Reader interactome of epigenetic histone marks in birds. Bluhm A, Casas-Vila N, Scheibe M, Butter F. Proteomics 16 427-436 (2016)
  78. Chromatin-prebound Crm1 recruits Nup98-HoxA9 fusion to induce aberrant expression of Hox cluster genes. Oka M, Mura S, Yamada K, Sangel P, Hirata S, Maehara K, Kawakami K, Tachibana T, Ohkawa Y, Kimura H, Yoneda Y. Elife 5 e09540 (2016)
  79. MicroRNAs regulate KDM5 histone demethylases in breast cancer cells. Denis H, Van Grembergen O, Delatte B, Dedeurwaerder S, Putmans P, Calonne E, Rothé F, Sotiriou C, Fuks F, Deplus R. Mol Biosyst 12 404-413 (2016)
  80. Co-regulation of histone-modifying enzymes in cancer. Islam AB, Richter WF, Jacobs LA, Lopez-Bigas N, Benevolenskaya EV. PLoS ONE 6 e24023 (2011)
  81. Critical role of retinoid/rexinoid signaling in mediating transformation and therapeutic response of NUP98-RARG leukemia. Qiu JJ, Zeisig BB, Li S, Liu W, Chu H, Song Y, Giordano A, Schwaller J, Gronemeyer H, Dong S, So CW. Leukemia 29 1153-1162 (2015)
  82. Genome-wide patterns of promoter sharing and co-expression in bovine skeletal muscle. Gu Q, Nagaraj SH, Hudson NJ, Dalrymple BP, Reverter A. BMC Genomics 12 23 (2011)
  83. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis. Struski S, Lagarde S, Bories P, Puiseux C, Prade N, Cuccuini W, Pages MP, Bidet A, Gervais C, Lafage-Pochitaloff M, Roche-Lestienne C, Barin C, Penther D, Nadal N, Radford-Weiss I, Collonge-Rame MA, Gaillard B, Mugneret F, Lefebvre C, Bart-Delabesse E, Petit A, Leverger G, Broccardo C, Luquet I, Pasquet M, Delabesse E. Leukemia 31 565-572 (2017)
  84. Synergistic Modification Induced Specific Recognition between Histone and TRIM24 via Fluctuation Correlation Network Analysis. Zhang J, Luo H, Liu H, Ye W, Luo R, Chen HF. Sci Rep 6 24587 (2016)
  85. The genomic landscape of pediatric myelodysplastic syndromes. Schwartz JR, Ma J, Lamprecht T, Walsh M, Wang S, Bryant V, Song G, Wu G, Easton J, Kesserwan C, Nichols KE, Mullighan CG, Ribeiro RC, Klco JM. Nat Commun 8 1557 (2017)
  86. PHF23 (plant homeodomain finger protein 23) negatively regulates cell autophagy by promoting ubiquitination and degradation of E3 ligase LRSAM1. Wang Z, Hu J, Li G, Qu L, He Q, Lou Y, Song Q, Ma D, Chen Y. Autophagy 10 2158-2170 (2014)
  87. Recruitment of the Mammalian Histone-modifying EMSY Complex to Target Genes Is Regulated by ZNF131. Varier RA, Carrillo de Santa Pau E, van der Groep P, Lindeboom RG, Matarese F, Mensinga A, Smits AH, Edupuganti RR, Baltissen MP, Jansen PW, Ter Hoeve N, van Weely DR, Poser I, van Diest PJ, Stunnenberg HG, Vermeulen M. J. Biol. Chem. 291 7313-7324 (2016)
  88. Distribution and prediction of catalytic domains in 2-oxoglutarate dependent dioxygenases. Kundu S. BMC Res Notes 5 410 (2012)
  89. Histone H3 proline 16 hydroxylation regulates mammalian gene expression. Liu X, Wang J, Boyer JA, Gong W, Zhao S, Xie L, Wu Q, Zhang C, Jain K, Guo Y, Rodriguez J, Li M, Uryu H, Liao C, Hu L, Zhou J, Shi X, Tsai YH, Yan Q, Luo W, Chen X, Strahl BD, von Kriegsheim A, Zhang Q, Wang GG, Baldwin AS, Zhang Q. Nat Genet 54 1721-1735 (2022)
  90. PHF13 is a molecular reader and transcriptional co-regulator of H3K4me2/3. Chung HR, Xu C, Fuchs A, Mund A, Lange M, Staege H, Schubert T, Bian C, Dunkel I, Eberharter A, Regnard C, Klinker H, Meierhofer D, Cozzuto L, Winterpacht A, Di Croce L, Min J, Will H, Kinkley S. Elife 5 (2016)
  91. ZMYND11-MBTD1 induces leukemogenesis through hijacking NuA4/TIP60 acetyltransferase complex and a PWWP-mediated chromatin association mechanism. Li J, Galbo PM, Gong W, Storey AJ, Tsai YH, Yu X, Ahn JH, Guo Y, Mackintosh SG, Edmondson RD, Byrum SD, Farrar JE, He S, Cai L, Jin J, Tackett AJ, Zheng D, Wang GG. Nat Commun 12 1045 (2021)
  92. An Epigenetic Mechanism Underlying Chromosome 17p Deletion-Driven Tumorigenesis. Chen M, Chen X, Li S, Pan X, Gong Y, Zheng J, Xu J, Zhao C, Zhang Q, Zhang S, Qi L, Wang Z, Shi K, Ding BS, Xue Z, Chen L, Yang S, Wang Y, Niu T, Dai L, Lowe SW, Chen C, Liu Y. Cancer Discov 11 194-207 (2021)
  93. Epigenetic Heterogeneity of B-Cell Lymphoma: Chromatin Modifiers. Hopp L, Nersisyan L, Löffler-Wirth H, Arakelyan A, Binder H. Genes (Basel) 6 1076-1112 (2015)
  94. Expression of Leukemia-Associated Nup98 Fusion Proteins Generates an Aberrant Nuclear Envelope Phenotype. Fahrenkrog B, Martinelli V, Nilles N, Fruhmann G, Chatel G, Juge S, Sauder U, Di Giacomo D, Mecucci C, Schwaller J. PLoS ONE 11 e0152321 (2016)
  95. Genome-wide analysis using ChIP to identify isoform-specific gene targets. Beshiri ML, Islam A, DeWaal DC, Richter WF, Love J, Lopez-Bigas N, Benevolenskaya EV. J Vis Exp (2010)
  96. HDAC inhibition through valproic acid modulates the methylation profiles in human embryonic kidney cells. Ganai SA, Kalladi SM, Mahadevan V. J. Biomol. Struct. Dyn. 33 1185-1197 (2015)
  97. Isolated Hoxa9 overexpression predisposes to the development of lymphoid but not myeloid leukemia. Beachy SH, Onozawa M, Silverman D, Chung YJ, Rivera MM, Aplan PD. Exp. Hematol. 41 518-529.e5 (2013)
  98. New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein. Kaelin WG. Ann. N. Y. Acad. Sci. 1210 1-7 (2010)
  99. ARID5B as a critical downstream target of the TAL1 complex that activates the oncogenic transcriptional program and promotes T-cell leukemogenesis. Leong WZ, Tan SH, Ngoc PCT, Amanda S, Yam AWY, Liau WS, Gong Z, Lawton LN, Tenen DG, Sanda T. Genes Dev. 31 2343-2360 (2017)
  100. Decoding chromatin goes high tech. Levy D, Gozani O. Cell 142 844-846 (2010)
  101. Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in Acute Myeloid Leukemia. Mohanty S, Jyotsana N, Sharma A, Kloos A, Gabdoulline R, Othman B, Lai CK, Schottmann R, Mandhania M, Schmoellerl J, Grebien F, Ramsay E, Thomas A, Vornlocher HP, Ganser A, Thol F, Heuser M. Cancers (Basel) 12 E2766 (2020)
  102. The fusion partner specifies the oncogenic potential of NUP98 fusion proteins. Saw J, Curtis DJ, Hussey DJ, Dobrovic A, Aplan PD, Slape CI. Leuk. Res. 37 1668-1673 (2013)
  103. A Drosophila Model of Intellectual Disability Caused by Mutations in the Histone Demethylase KDM5. Zamurrad S, Hatch HAM, Drelon C, Belalcazar HM, Secombe J. Cell Rep 22 2359-2369 (2018)
  104. CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. Schmoellerl J, Barbosa IAM, Eder T, Brandstoetter T, Schmidt L, Maurer B, Troester S, Pham HTT, Sagarajit M, Ebner J, Manhart G, Aslan E, Terlecki-Zaniewicz S, Van der Veen C, Hoermann G, Duployez N, Petit A, Lapillonne H, Puissant A, Itzykson R, Moriggl R, Heuser M, Meisel R, Valent P, Sexl V, Zuber J, Grebien F. Blood 136 387-400 (2020)
  105. Functional analysis of the NUP98-CCDC28A fusion protein. Petit A, Ragu C, Soler G, Ottolenghi C, Schluth C, Radford-Weiss I, Schneider-Maunoury S, Callebaut I, Dastugue N, Drabkin HA, Bernard OA, Romana S, Penard-Lacronique V. Haematologica 97 379-387 (2012)
  106. Histone H3Q5 serotonylation stabilizes H3K4 methylation and potentiates its readout. Zhao S, Chuh KN, Zhang B, Dul BE, Thompson RE, Farrelly LA, Liu X, Xu N, Xue Y, Roeder RG, Maze I, Muir TW, Li H. Proc Natl Acad Sci U S A 118 e2016742118 (2021)
  107. Massively parallel knock-in engineering of human T cells. Dai X, Park JJ, Du Y, Na Z, Lam SZ, Chow RD, Renauer PA, Gu J, Xin S, Chu Z, Liao C, Clark P, Zhao H, Slavoff S, Chen S. Nat Biotechnol 41 1239-1255 (2023)
  108. Shaping the p53 response with nucleoporins. Yarbrough ML, White MA, Fontoura BM. Mol. Cell 48 665-666 (2012)
  109. The new nucleoporin: regulator of transcriptional repression and beyond. Sarma NJ, Willis K. Nucleus 3 508-515 (2012)
  110. A conserved BAH module within mammalian BAHD1 connects H3K27me3 to Polycomb gene silencing. Fan H, Guo Y, Tsai YH, Storey AJ, Kim A, Gong W, Edmondson RD, Mackintosh SG, Li H, Byrum SD, Tackett AJ, Cai L, Wang GG. Nucleic Acids Res 49 4441-4455 (2021)
  111. Letter Cryptic genomic lesions in adverse-risk acute myeloid leukemia identified by integrated whole genome and transcriptome sequencing. Kim JC, Zuzarte PC, Murphy T, Chan-Seng-Yue M, Brown AMK, Krzyzanowski PM, Smith AC, Notta F, Minden MD, McPherson JD. Leukemia 34 306-311 (2020)
  112. Genomic subtyping and therapeutic targeting of acute erythroleukemia. Iacobucci I, Wen J, Meggendorfer M, Choi JK, Shi L, Pounds SB, Carmichael CL, Masih KE, Morris SM, Lindsley RC, Janke LJ, Alexander TB, Song G, Qu C, Li Y, Payne-Turner D, Tomizawa D, Kiyokawa N, Valentine M, Valentine V, Basso G, Locatelli F, Enemark EJ, Kham SKY, Yeoh AEJ, Ma X, Zhou X, Sioson E, Rusch M, Ries RE, Stieglitz E, Hunger SP, Wei AH, To LB, Lewis ID, D'Andrea RJ, Kile BT, Brown AL, Scott HS, Hahn CN, Marlton P, Pei D, Cheng C, Loh ML, Ebert BL, Meshinchi S, Haferlach T, Mullighan CG. Nat. Genet. 51 694-704 (2019)
  113. Letter Identification of the NUP98-PHF23 fusion gene in pediatric cytogenetically normal acute myeloid leukemia by whole-transcriptome sequencing. Togni M, Masetti R, Pigazzi M, Astolfi A, Zama D, Indio V, Serravalle S, Manara E, Bisio V, Rizzari C, Basso G, Pession A, Locatelli F. J Hematol Oncol 8 69 (2015)
  114. KDM5 histone demethylases repress immune response via suppression of STING. Wu L, Cao J, Cai WL, Lang SM, Horton JR, Jansen DJ, Liu ZZ, Chen JF, Zhang M, Mott BT, Pohida K, Rai G, Kales SC, Henderson MJ, Hu X, Jadhav A, Maloney DJ, Simeonov A, Zhu S, Iwasaki A, Hall MD, Cheng X, Shadel GS, Yan Q. PLoS Biol. 16 e2006134 (2018)
  115. Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma. Ohguchi H, Park PMC, Wang T, Gryder BE, Ogiya D, Kurata K, Zhang X, Li D, Pei C, Masuda T, Johansson C, Wimalasena VK, Kim Y, Hino S, Usuki S, Kawano Y, Samur MK, Tai YT, Munshi NC, Matsuoka M, Ohtsuki S, Nakao M, Minami T, Lauberth S, Khan J, Oppermann U, Durbin AD, Anderson KC, Hideshima T, Qi J. Blood Cancer Discov 2 370-387 (2021)
  116. Modulation of thyroid hormone-dependent gene expression in Xenopus laevis by INhibitor of Growth (ING) proteins. Helbing CC, Wagner MJ, Pettem K, Johnston J, Heimeier RA, Veldhoen N, Jirik FR, Shi YB, Browder LW. PLoS ONE 6 e28658 (2011)
  117. Molecular structures guide the engineering of chromatin. Tekel SJ, Haynes KA. Nucleic Acids Res. 45 7555-7570 (2017)
  118. Poly(ADP-ribose) binding and macroH2A mediate recruitment and functions of KDM5A at DNA lesions. Kumbhar R, Sanchez A, Perren J, Gong F, Corujo D, Medina F, Devanathan SK, Xhemalce B, Matouschek A, Buschbeck M, Buck-Koehntop BA, Miller KM. J Cell Biol 220 e202006149 (2021)
  119. Regulation of differentiation by a PHD domain in the NUP98-PHF23 fusion protein. Reader JC, Leng Q, Rassool FV, Ning Y. Leuk. Res. 34 1094-1097 (2010)
  120. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Heikamp EB, Henrich JA, Perner F, Wong EM, Hatton C, Wen Y, Barwe SP, Gopalakrishnapillai A, Xu H, Uckelmann HJ, Takao S, Kazansky Y, Pikman Y, McGeehan GM, Kolb EA, Kentsis A, Armstrong SA. Blood 139 894-906 (2022)
  121. BRD4 inhibitor IBET upregulates p27kip/cip protein stability in neuroendocrine tumor cells. Wang L, Matkar S, Xie G, An C, He X, Kong X, Liu X, Hua X. Cancer Biol. Ther. 18 229-236 (2017)
  122. Discovery and Mechanism of Small Molecule Inhibitors Selective for the Chromatin-Binding Domains of Oncogenic UHRF1. Liu WH, Miner RE, Albaugh BN, Ananiev GE, Wildman SA, Denu JM. Biochemistry 61 354-366 (2022)
  123. HP1γ Promotes Lung Adenocarcinoma by Downregulating the Transcription-Repressive Regulators NCOR2 and ZBTB7A. Alam H, Li N, Dhar SS, Wu SJ, Lv J, Chen K, Flores ER, Baseler L, Lee MG. Cancer Res. 78 3834-3848 (2018)
  124. Integrative genomic and transcriptomic analysis for pinpointing recurrent alterations of plant homeodomain genes and their clinical significance in breast cancer. Yu H, Jiang Y, Liu L, Shan W, Chu X, Yang Z, Yang ZQ. Oncotarget 8 13099-13115 (2017)
  125. Recognition of Histone H3 Methylation States by the PHD1 Domain of Histone Demethylase KDM5A. Longbotham JE, Kelly MJS, Fujimori DG. ACS Chem Biol (2021)
  126. The Chromatin Remodeler BPTF Activates a Stemness Gene-Expression Program Essential for the Maintenance of Adult Hematopoietic Stem Cells. Xu B, Cai L, Butler JM, Chen D, Lu X, Allison DF, Lu R, Rafii S, Parker JS, Zheng D, Wang GG. Stem Cell Reports 10 675-683 (2018)
  127. The effect of the length of histone H3K4me3 on recognition by reader proteins. Pieters B, Belle R, Mecinović J. Chembiochem 14 2408-2412 (2013)
  128. Translocation t(11;17) in de novo myelodysplastic syndrome not associated with acute myeloid or acute promyelocytic leukemia. Baljevic M, Abdel-Wahab O, Rampal R, Maslak PG, Klimek VM, Rosenblat TL, Douer D, Levine RL, Tallman MS. Acta Haematol. 129 48-54 (2013)
  129. E2A-PBX1 functions as a coactivator for RUNX1 in acute lymphoblastic leukemia. Pi WC, Wang J, Shimada M, Lin JW, Geng H, Lee YL, Lu R, Li D, Wang GG, Roeder RG, Roeder RG, Chen WY. Blood 136 11-23 (2020)
  130. Histone-binding of DPF2 mediates its repressive role in myeloid differentiation. Huber FM, Greenblatt SM, Davenport AM, Martinez C, Xu Y, Vu LP, Nimer SD, Hoelz A. Proc. Natl. Acad. Sci. U.S.A. 114 6016-6021 (2017)
  131. Mechanism of biomolecular recognition of trimethyllysine by the fluorinated aromatic cage of KDM5A PHD3 finger. Pieters BJGE, Wuts MHM, Poater J, Kumar K, White PB, Kamps JJAG, Sherman W, Pruijn GJM, Paton RS, Beuming T, Bickelhaupt FM, Mecinović J. Commun Chem 3 69 (2020)
  132. Phase Separation Mediates NUP98 Fusion Oncoprotein Leukemic Transformation. Chandra B, Michmerhuizen NL, Shirnekhi HK, Tripathi S, Pioso BJ, Baggett DW, Mitrea DM, Iacobucci I, White MR, Chen J, Park CG, Wu H, Pounds S, Medyukhina A, Khairy K, Gao Q, Qu C, Abdelhamed S, Gorman SD, Bawa S, Maslanka C, Kinger S, Dogra P, Ferrolino MC, Di Giacomo D, Mecucci C, Klco JM, Mullighan CG, Kriwacki RW. Cancer Discov 12 1152-1169 (2022)
  133. The Role of Electrostatic Interactions in Binding of Histone H3K4me2/3 to the Sgf29 Tandem Tudor Domain. Pieters BJ, Meulenbroeks E, Belle R, Mecinović J. PLoS ONE 10 e0139205 (2015)
  134. The SQSTM1-NUP214 fusion protein interacts with Crm1, activates Hoxa and Meis1 genes, and drives leukemogenesis in mice. Lavau CP, Aumann WK, Sze SK, Gupta V, Ripple K, Port SA, Kehlenbach RH, Wechsler DS. PLoS One 15 e0232036 (2020)
  135. ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Cai L, Tsai YH, Wang P, Wang J, Li D, Fan H, Zhao Y, Bareja R, Lu R, Wilson EM, Sboner A, Whang YE, Zheng D, Parker JS, Earp HS, Wang GG. Mol. Cell 72 341-354.e6 (2018)
  136. A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia. Ren Z, Kim A, Huang YT, Pi WC, Gong W, Yu X, Qi J, Jin J, Cai L, Roeder RG, Chen WY, Wang GG. Proc Natl Acad Sci U S A 119 e2122940119 (2022)
  137. BAHCC1 binds H3K27me3 via a conserved BAH module to mediate gene silencing and oncogenesis. Fan H, Lu J, Guo Y, Li D, Zhang ZM, Tsai YH, Pi WC, Ahn JH, Gong W, Xiang Y, Allison DF, Geng H, He S, Diao Y, Chen WY, Strahl BD, Cai L, Song J, Wang GG. Nat Genet 52 1384-1396 (2020)
  138. BMI1 suffers a degrading experience. Hoenerhoff M, Chu IM, Green JE. Cell Cycle 10 1894-1895 (2011)
  139. Biomolecular condensation of NUP98 fusion proteins drives leukemogenic gene expression. Terlecki-Zaniewicz S, Humer T, Eder T, Schmoellerl J, Heyes E, Manhart G, Kuchynka N, Parapatics K, Liberante FG, Müller AC, Tomazou EM, Grebien F. Nat Struct Mol Biol 28 190-201 (2021)
  140. CHD7 regulates bone-fat balance by suppressing PPAR-γ signaling. Liu C, Xiong Q, Li Q, Lin W, Jiang S, Zhang D, Wang Y, Duan X, Gong P, Kang N. Nat Commun 13 1989 (2022)
  141. Chagas disease: transcriptomic recovery in animal models after transplantation of bone marrow cells. Morel CM. Cell Cycle 10 1892 (2011)
  142. Chromatin Sensing by the Auxiliary Domains of KDM5C Regulates Its Demethylase Activity and Is Disrupted by X-linked Intellectual Disability Mutations. Ugur FS, Kelly MJS, Fujimori DG. J Mol Biol 435 167913 (2023)
  143. Clinicopathological features and genomic profiles of a group of secretory breast carcinomas in which progressive cases have more complex genomic features. Lei T, Yang Y, Shi Y, Deng X, Peng Y, Wang H, Chen T. Diagn Pathol 17 101 (2022)
  144. Cyclic peptides target the aromatic cage of a PHD-finger reader domain to modulate epigenetic protein function. Coleman OD, Macdonald J, Thomson B, Ward JA, Stubbs CJ, McAllister TE, Clark S, Amin S, Cao Y, Abboud MI, Zhang Y, Sanganee H, Huber KVM, Claridge TDW, Kawamura A. Chem Sci 14 7136-7146 (2023)
  145. Dynamic site-specific recruitment of RBP2 by pocket protein p130 modulates H3K4 methylation on E2F-responsive promoters. Zargar ZU, Kimidi MR, Tyagi S. Nucleic Acids Res. 46 174-188 (2018)
  146. E2F6/KDM5C promotes SF3A3 expression and bladder cancer progression through a specific hypomethylated DNA promoter. Liu KL, Yin YW, Lu BS, Niu YL, Wang DD, Shi B, Zhang H, Guo PY, Yang Z, Li W. Cancer Cell Int 22 109 (2022)
  147. Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription. Frigault MM, Mithal A, Wong H, Stelte-Ludwig B, Mandava V, Huang X, Birkett J, Johnson AJ, Izumi R, Hamdy A. Cancer Res Commun 3 2268-2279 (2023)
  148. Epigenetic Reprogramming of the Glucose Metabolic Pathways by the Chromatin Effectors During Cancer. Mondal P, Tiwary N, Sengupta A, Dhang S, Roy S, Das C. Subcell Biochem 100 269-336 (2022)
  149. Expansion microscopy allows high resolution single cell analysis of epigenetic readers. Acke A, Van Belle S, Louis B, Vitale R, Rocha S, Voet T, Debyser Z, Hofkens J. Nucleic Acids Res 50 e100 (2022)
  150. Extended Recognition of the Histone H3 Tail by Histone Demethylase KDM5A. Petronikolou N, Longbotham JE, Fujimori DG. Biochemistry 59 647-651 (2020)
  151. GATA3 Exerts Distinct Transcriptional Functions to Regulate Radiation Resistance in A549 and H1299 Cells. Wang R, Yi J, Gao H, Wei X, Shao L, Wang M, Xu W, Yin X, Shen Y, Wang Z, Wei W, Jin S. Oxid Med Cell Longev 2022 9174111 (2022)
  152. Generation of a H9 Clonal Cell Line With Inducible Expression of NUP98-KDM5A Fusion Gene in the AAVS1 Safe Harbor Locus. Domingo-Reinés J, Martínez-Navajas G, Montes R, Lamolda M, Simón I, Castaño J, Ríos-Pelegrina R, Lopez-Hidalgo JL, García Del Moral R, Marchal JA, Real PJ, Ramos-Mejía V. Front Cell Dev Biol 10 846092 (2022)
  153. Genetic Evidence for Early Peritoneal Spreading in Pelvic High-Grade Serous Cancer. Chien J, Neums L, Powell AFLA, Torres M, Kalli KR, Multinu F, Shridhar V, Mariani A. Front Oncol 8 58 (2018)
  154. High-throughput strategy to identify inhibitors of histone-binding domains. Wagner EK, Albaugh BN, Denu JM. Meth. Enzymol. 512 161-185 (2012)
  155. Histone H3 binding to the PHD1 domain of histone demethylase KDM5A enables active site remodeling. Longbotham JE, Chio CM, Dharmarajan V, Trnka MJ, Torres IO, Goswami D, Ruiz K, Burlingame AL, Griffin PR, Fujimori DG. Nat Commun 10 94 (2019)
  156. Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities. Cardin S, Bilodeau M, Roussy M, Aubert L, Milan T, Jouan L, Rouette A, Laramée L, Gendron P, Duchaine J, Decaluwe H, Spinella JF, Mourad S, Couture F, Sinnett D, Haddad É, Landry JR, Ma J, Humphries RK, Roux PP, Hébert J, Gruber TA, Wilhelm BT, Cellot S. Blood Adv 3 3307-3321 (2019)
  157. Identification of 113 new histone marks by CHiMA, a tailored database search strategy. Gao J, Sheng X, Du J, Zhang D, Han C, Chen Y, Wang C, Zhao Y. Sci Adv 9 eadf1416 (2023)
  158. Identification of Key Histone Modifications and Their Regulatory Regions on Gene Expression Level Changes in Chronic Myelogenous Leukemia. Zhang LQ, Fan GL, Liu JJ, Liu L, Li QZ, Lin H. Front Cell Dev Biol 8 621578 (2020)
  159. Identification of ryuvidine as a KDM5A inhibitor. Mitsui E, Yoshida S, Shinoda Y, Matsumori Y, Tsujii H, Tsuchida M, Wada S, Hasegawa M, Ito A, Mino K, Onuki T, Yoshida M, Sasaki R, Mizukami T. Sci Rep 9 9952 (2019)
  160. KDM5 Lysine Demethylases in Pathogenesis, from Basic Science Discovery to the Clinic. Zhang SM, Cao J, Yan Q. Adv Exp Med Biol 1433 113-137 (2023)
  161. KDM5A Regulates a Translational Program that Controls p53 Protein Expression. Hu D, Jablonowski C, Cheng PH, AlTahan A, Li C, Wang Y, Palmer L, Lan C, Sun B, Abu-Zaid A, Fan Y, Brimble M, Gamboa NT, Kumbhar RC, Yanishevski D, Miller KM, Kang G, Zambetti GP, Chen T, Yan Q, Davidoff AM, Yang J. iScience 9 84-100 (2018)
  162. Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies. Michmerhuizen NL, Klco JM, Mullighan CG. Blood 136 2275-2289 (2020)
  163. Missense Variants Reveal Functional Insights Into the Human ARID Family of Gene Regulators. Deák G, Cook AG. J Mol Biol 434 167529 (2022)
  164. NUP98-BPTF gene fusion identified in primary refractory acute megakaryoblastic leukemia of infancy. Roussy M, Bilodeau M, Jouan L, Tibout P, Laramée L, Lemyre E, Léveillé F, Tihy F, Cardin S, Sauvageau C, Couture F, Louis I, Choblet A, Patey N, Gendron P, Duval M, Teira P, Hébert J, Wilhelm BT, Choi JK, Gruber TA, Bittencourt H, Cellot S. Genes Chromosomes Cancer 57 311-319 (2018)
  165. Nuclear Envelope Regulation of Oncogenic Processes: Roles in Pancreatic Cancer. Preston CC, Faustino RS. Epigenomes 2 (2018)
  166. Proximity labeling reveals a new in vivo network of interactors for the histone demethylase KDM5. Yheskel M, Sidoli S, Secombe J. Epigenetics Chromatin 16 8 (2023)
  167. Reading and erasing of the phosphonium analogue of trimethyllysine by epigenetic proteins. Belle R, Kamps JJAG, Poater J, Kumar K, Pieters BJGE, Salah E, Claridge TDW, Paton RS, Bickelhaupt FM, Kawamura A, Schofield CJ, Mecinović J. Commun Chem 5 27 (2022)
  168. Structural insights into trans-histone regulation of H3K4 methylation by unique histone H4 binding of MLL3/4. Liu Y, Qin S, Chen TY, Lei M, Dhar SS, Ho JC, Dong A, Loppnau P, Li Y, Lee MG, Min J. Nat Commun 10 36 (2019)
  169. Editorial Synthetic human leukemia models: towards precision medicine. Cellot S, Wilhelm BT, Barabé F. Oncotarget 8 96480-96481 (2017)
  170. The Histone Demethylase KDM5 Is Essential for Larval Growth in Drosophila. Drelon C, Belalcazar HM, Secombe J. Genetics 209 773-787 (2018)
  171. The Retinoblastoma Tumor Suppressor Is Required for the NUP98-HOXA9-Induced Aberrant Nuclear Envelope Phenotype. Vaz M, Fahrenkrog B. Cells 10 2851 (2021)
  172. The histone H3K4 demethylase JARID1A directly interacts with haematopoietic transcription factor GATA1 in erythroid cells through its second PHD domain. Karia D, Gilbert RCG, Biasutto AJ, Porcher C, Mancini EJ. R Soc Open Sci 7 191048 (2020)
  173. The pediatric leukemia oncoprotein NUP98-KDM5A induces genomic instability that may facilitate malignant transformation. Domingo-Reinés J, Montes R, Garcia-Moreno A, Gallardo A, Sanchez-Manas JM, Ellson I, Lamolda M, Calabro C, López-Escamez JA, Catalina P, Carmona-Sáez P, Real PJ, Landeira D, Ramos-Mejia V. Cell Death Dis 14 357 (2023)
  174. Transcriptomics of cardiac biopsies reveals differences in patients with or without diagnostic parameters for heart failure with preserved ejection fraction. Das S, Frisk C, Eriksson MJ, Walentinsson A, Corbascio M, Hage C, Kumar C, Asp M, Lundeberg J, Maret E, Persson H, Linde C, Persson B. Sci Rep 9 3179 (2019)


Quick links